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Dr Theodore Teruya (Loma Linda, Calif). The authors
found that patients who use insulin as either monotherapy or in
combination with oral hypoglycemic agents had worse limb sal-
vage and survival.
It is well known that tight glycemic control can limit the
complications of diabetes. Did the authors measure hemoglobin
A1c levels and, if so, were they significantly different in the groups
with diabetes? Was the use of insulin just a marker of poor glycemic
control?
We also know that the most frequent cause of limb loss in
diabetics is due to pedal sepsis and not critical limb ischemia. How
many patients suffered limb loss due to overwhelming infections orscript here at this meeting in 2002 that showed that 24% of major
amputations performed were from pedal sepsis or extensive tissue
loss.
Finally, what was the rationale for including patients without
critical limb ischemia (ie, the claudication group) in this study?
There were more claudicants in the nondiabetic and oral hypogly-
cemic agent groups, than in the groups that took insulin. Do you
think this affected the outcome of the study?
Dr Dosluoglu. This is a retrospective study, and that’s the
weakness of the study. I tried to see if the patients did have data on
hemoglobin A1c levels. It was really not very reliably found. So I’m
not going to be able to give you any data on the tight control vs
long-term or short-term on this subgroup, but I agree with you.
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be a reflection of other end products of poor diabetes control as
well, so we are planning on prospectively evaluating this in the
future. I truly believe though this may be not only tight control,
but it is a reflection of the level of diabetes affecting the outcomes.
As to the last question, we did include the diabetics and
claudicants to see if there were patency differences, as was sug-
gested by the University of Rochester paper. I actually analyzed
them separately so that we could actually iron that out in terms of
outcomes.
Lastly, the infection-related amputations were clearly more
common in the insulin group than others. I looked at it also; it was
about 50% of the patients who had infection-related amputation.
We just recently wrote a paper, which was published in the June
issue of the Journal, on the limb loss with patent endovascular-treated segments, in which we observed that a lot of the amputa-
tions occurred in patients with patent stents, which is a reflection of
our aggressiveness in that we try to save these limbs, and we lose
some due to infections. It may be related to poor glucose control,
but I do not have the specific data for that.
Dr Jonathan Eliason (Ann Arbor, Mich). Was there any
consideration to look at the type of insulin control that patients
had: long-acting, sliding-scale–based, older formulations, or
newer formulations, and whether or not there is a difference? I
know it’s tough to tease those out.
Dr Dosluoglu. It could be done. That’s easier than getting
the hemoglobin A1c, because hemoglobin A1c was not necessarily
obtained in a lot of these, so I cannot really get that. Due to the
large number of patients, this would require a lot of effort, and we
elected not to do that for this study.
